Drug Trial Radar · NCT04774393
Decitabine/Cedazuridine and Venetoclax in Combination With Ivosidenib or Enasidenib for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia
Last checked: Nov 20, 2026Latest source record: Nov 12, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
84
Planned (sponsor's estimate)
Start
May 24, 2021
Primary completion
Nov 29, 2027
Study completion Nov 29, 2027
Sponsor
- Lead sponsor
- M.D. Anderson Cancer CenterAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Mar 1, 2021
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Non randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This phase Ib/II trials studies the side effects of decitabine/cedazuridine (ASTX727) and venetoclax in combination with ivosidenib or enasidenib, and how well they work in treating patients with acute myeloid leukemia that has come back (relapsed) or does not respond to treatment (refractory). ASTX727 is the combination of a fixed dose of 2 drugs, cedazuridine and decitabine. Cedazuridine may slow down how fast decitabine is broken down by the body, and decitabine may block abnormal cells or cancer cells from growing. Venetoclax may stop the growth of cancer cells by blocking BCL-2, a protein needed for cancer cell survival. Enasidenib and ivosidenib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Giving decitabine/cedazuridine and venetoclax in combination with ivosidenib or enasidenib may help control acute myeloid leukemia.
Conditions
- Acute Myeloid Leukemia
- Recurrent Acute Myeloid Leukemia
- Refractory Acute Myeloid Leukemia
Interventions
Decitabine and CedazuridineDrug
Given PO
EnasidenibDrug
Given PO
IvosidenibDrug
Given PO
VenetoclaxDrug
Given PO
Primary outcomes
What the sponsor says the trial is designed to measure.
- Dose limiting toxicity (Phase Ib)Time frame: Up to 1 cycle (1 cycle = 28 days)
- Overall response rate (ORR) (Phase II)Time frame: Within 4 months of treatment
- Incidence of adverse events (Phase II)Time frame: Within 4 months of treatment
Locations
1 site in 1 country. Site status is shown where the registry gives one.
M D Anderson Cancer Center
Houston, Texas · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.